

Clinical disease characteristics of patients with Niemann-Pick Disease Type C – findings from the International Niemann-Pick Disease Registry (INPDR)

Shaun Christopher Bolton (✉ shaun.bolton@uhb.nhs.uk)

University Hospital Birmingham NHS Foundation Trust <https://orcid.org/0000-0003-0160-1505>

Vina Soran

University of Birmingham

Mercedes Pineda Marfa

Hospital Sant Joan de Deu

Jackie Imrie

International Niemann-Pick Disease Registry

Paul Gissen

University College London

Helena Jahnova

Charles University: Univerzita Karlova

Reena Sharma

Salford Royal Hospitals NHS Trust: Salford Royal NHS Foundation Trust

Simon Jones

Central Manchester Healthcare NHS Trust: Manchester University NHS Foundation Trust

Saikat Santra

Birmingham Children's Hospital NHS Foundation Trust: Birmingham Women's and Children's NHS Foundation Trust

Ellen Crushell

Children's Health Ireland at Temple Street

Miriam Stampfer

Universitätsklinikum Tübingen: Universitätsklinikum Tübingen

Maria Jose Coll

Hospital Clinic de Barcelona

Charlotte Dawson

University Hospitals Birmingham NHS Foundation Trust

Toni Mathieson

International Niemann-Pick Disease Registry

James Green

International Niemann-Pick Disease Registry

Andrea Dardis

Hospital Santa Maria della Misericordia di Udine

Bruno Bembi

Hospital Santa Maria della Misericordia di Udine

Marc Patterson

Mayo Clinic Department of Pediatric and Adolescent Medicine

Marie T Vanier

INSERM

Tarekegn Geberhiwot

University Hospitals Birmingham NHS Foundation Trust

Research Article

Keywords: Niemann-Pick Disease Type C (NPC), NPC clinical data, clinical disease characteristics, International Niemann-Pick Disease Registry (INPDR)

Posted Date: September 28th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-934191/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Orphanet Journal of Rare Diseases on February 14th, 2022. See the published version at <https://doi.org/10.1186/s13023-022-02200-4>.

Abstract

Background

Niemann-Pick Disease Type C (NPC) is an autosomal recessive rare disease characterised by progressive neurovisceral manifestations. The collection of on-going large-scale NPC clinical data may generate better understandings of the natural history of the disease. Here we report NPC patient data from the International Niemann-Pick Disease Registry (INPDR).

Method

The INPDR is a web-based, patient-led independent registry for the collection of prospective and retrospective clinical data from Niemann-Pick Disease patients. Baseline data from NPC patients enrolled into the INPDR from September 2014 to December 2019 was extracted to analyse the demographic, genetic and clinical features.

Results

A total of 203 NPC patients from six European countries were included in this study. The mean age (SD) at diagnosis was 11.2 years (14.2). Among enrolled patients, 168 had known neurological manifestations; 43 (24.2%) had early-infantile onset, 47 (26.4%) had late-infantile onset, 41 (23.0%) had juvenile onset, and 37 (20.8%) had adult onset. 10 (5.6%) patients had the neonatal rapidly fatal systemic form. Among the 97 patients with identified NPC1 variants, the most common variant was the c. 3182T > C variant responsible for the p.Ile1061Thr protein change, reported in 35.1% (N = 34) of patients. The frequencies of hepatomegaly and neonatal jaundice were greatest in patients with early-infantile and late-infantile onset. Splenomegaly was the most commonly reported observation, including 80% of adult-onset patients. The most commonly reported neurological manifestations were cognitive impairment (78.5%), dysarthria (75.9%), ataxia (75.9%), vertical supranuclear gaze palsy (VSGP) (70.9%), dysphagia (69.6%). A 6-domain composite disability scale was used to calculate the overall disability score according to neurological-onset. Across all with neurological onset, the majority of patients showed moderate to severe impairments in all domains, excluding 'swallowing' and 'seizure'. The age at diagnosis and death increased with increased age of neurological symptom onset. Miglustat use was recorded in 62.43% of patients and the most common symptomatic therapies used by patients were antiepileptics (32.94%), antidepressants (11.76%) and antacids (9.41%).

Conclusion

The proportion of participants at each age of neurological onset was relatively consistent across the cohort. Neurological manifestations, such as ataxia, dysphagia, and dysarthria, were frequently observed

across all age categories.

Introduction

Niemann-Pick Disease Type C (NPC) is a rare, autosomal recessive disorder resulting from variations to either the *NPC1* or *NPC2* gene. Pathogenic variants in either gene lead to the impaired movement of cholesterol and lipids out of the lysosome and late endosome, resulting in the accumulation of lipids within the affected cell (1). Advances in diagnostics, disease modifying therapy and disease awareness have led to the recognition of NPC as a heterogeneous disease, ranging from a fatal antenatal disorder to an adult-onset chronic neurodegenerative disease.

The clinical spectrum of NPC encompasses a range of neurological and systemic manifestations at an early stage being non-specific and varies by age of onset and organ involvement. Disease onset in early infancy including the neonatal period is typically characterised by visceral manifestations such as neonatal cholestatic jaundice, hepatosplenomegaly, with, in a small subset of patients, rapid progression into liver and respiratory failure leading to death (2). At childhood or older age, neurological manifestations become prevalent, such as hypotonia, gelastic cataplexy, ataxia, dysarthria, dysphagia, vertical supranuclear gaze palsy (VSGP), seizures and cognitive impairment. Psychiatric symptoms are also prevalent in older NPC patients (2). NPC is a chronic and progressive disease, with the rate of progression varying between individuals, including between siblings (3). Age at neurological manifestation is recognised as a predictor of disease progression.

The rarity, varied age of onset, heterogeneous and non-specific manifestation of the disease poses a significant challenge in understanding the natural course of NPC. Observational studies of NPC patients across developed nations have been reported, with data from France, Spain, the UK and USA (4–9). These studies have advanced the understanding of NPC as a spectrum disorder, leading to enhanced care for NPC patients. The consolidation of existing data alongside the generation of new data via an international patient registry may lead to the improved characterisation of NPC.

Here we report the findings of an analysis of Niemann-Pick Disease Type C data currently gathered through the International Niemann-Pick Disease Registry. We have developed an exemplar patient led independent international registry capable of providing an inventory of patients for recruitment to observational and interventional studies.

Results

Demographics, patient characteristics, biochemical and genetic diagnostics

A total of 203 patients have been enrolled from 11 NPD centres across 6 countries: The Czech Republic, Germany, Ireland, Italy, Spain and the UK. A summary of patient and disease characteristics stratified by

age at neurological onset categories are described in Table 1. The study participants were equally split in sex with 49.8 % male and 50.2% female. 39.9% of patients were prospective records. The mean (SD) age at diagnosis was 11.2 (14.2) years. Of the 203 patients enrolled, 178 patients had known neurological manifestations at the point of data collection. Forty-three (24.2%) had early-infantile onset, 47 (26.4%) had late infantile onset, 41 (23.0%) had juvenile onset, and 37 (20.8%) had adult onset. Of the remaining 35 patients, 10 (5.6%) had the neonatal rapidly fatal form, 21 patients were reported as not having neurological manifestations, and 4 patients having visceral symptoms only.

Table 1
Demographics, clinical and diagnostic characteristics of patients with NPC disease.

Characteristic	n (%)	Mean (SD)
Overall population (n = 203)		
Male:	101 (49.8)	-
Female	102 (50.2)	
Age at diagnosis	203	11.2 (14.2)
Age at enrolment (years)	203	25.8 (16.5)
Prospective patient records	81 (39.9)	-
Retrospective patient records	122 (60.1)	-
Patients with neurological manifestations (n = 178)		
	n (%)	Mean Age at Diagnosis (SD) & Range in years
Neonatal rapidly fatal (0–28 days)	10 (5.6)	0.37 (0.25) – 0–0.9
Early infantile neurological (< 2 years)	43 (24.2)	2.16 (2.75) – 0–17
Late infantile neurological (2 - <6 years)	47 (26.4)	4.92 (3.25) – 0.1–12
Juvenile neurological (6- <15 years)	41 (23.0)	9.89 (5.34) – 0.1–22
Adult neurological (> 15 years)	37 (20.8)	34.12 (13.84) – 1.4–68.1
No neurological manifestations	4 (2.2%)	19 (17.95) – 0.7–42
Variant analysis - NPC1 (n = 97)		
	n (%)	
c.3182T > C (p.I1061T)	28 (28.6)	
c.3019C > G (p.P1007A)	10 (10.2)	
c.3557G > A (p.R1186H)	9 (9.2)	
Cholestane-triol (n = 27)		
	n (%)	
Elevated	23 (85)	
Borderline	2 (7)	

Characteristic	n (%)	Mean (SD)
Normal	2 (7)	
Neuroimaging assessment		
MRI (n = 49)		
	n (%)	
Normal	29 (59)	
Abnormal	20 (41)	
Cortical Atrophy	10 (50)	
Cerebellar Atrophy	9 (45)	
White matter change	5 (25)	
CT (n = 7)		
	n (%)	
Normal	6 (86)	
Abnormal - Cortical Atrophy	1 (14)	

DNA testing was recorded for 98 patients; among them 97 presented biallelic variants in *NPC1* gene and 1 patient had variants in *NPC2* gene. Regarding *NPC1* gene variants, an important heterogeneity in the genotypes was observed and the majority of patients were compound heterozygous. The most common *NPC1* variant was the c.3182T > C (p.Ile1061Thr) variant related with the classical biochemical phenotype and with the juvenile clinical form of presentation. The p.I1061T variant was reported in 28.6% (N = 28) of patients, with a total number of 28 alleles. Secondly, the c.3019C > G (p.P1007A) variant was reported in 10.2% of patients (N = 10) and related with the variant biochemical phenotype and with the juvenile-adult forms of the disease. A total of 9 alleles were reported for the variant. Finally, the c.3557G > A (p.R1186H) variant was reported in 9.2% of patients (N = 9). The mean age at which genetic testing was performed was 10.7 years old. Plasma levels of Cholestane-triol were documented in 27 patients, 23 of them presented levels above the cut-off, 2 showed borderline concentrations and 2 displayed normal values.

Clinical Features

Systemic Manifestations

Systemic manifestations consisting of neonatal jaundice, spleen and liver enlargement and liver failure was recorded for 81 patients and are summarised in Fig. 1. The proportion of patients who developed splenomegaly was 72.8%, whilst hepatomegaly was reported in 39.5% of patients. Similarly, neonatal jaundice was noted in 39.5% of patients, and hepatic failure in the neonatal period was 6.2%. The proportion of patients with neonatal jaundice, spleno- and hepatomegaly decreased with increasing age of neurological onset.

Neurological Manifestations

The profiles of patients with neurological manifestations according to the age-at-neurological-onset is summarised in Fig. 2a. The most common neurological manifestations reported include cognitive impairment (78.5%), dysarthria (75.9%), ataxia (75.9%), vertical supranuclear gaze palsy (VSGP) (70.9%), dysphagia (69.6%), dystonia (53.2%), seizures (48.1%), and cataplexy (35.4%). Overall, the late infantile onset subgroup made up the highest proportion of neurological manifestations, with the exception of psychiatric manifestations and cognitive impairment. The latter two components were predominant in adult onset phenotype. The least prevalent neurological manifestations were psychiatric manifestations (13.9%) and hearing impairment (7.6%).

Developmental milestone data stratified according to age at neurological onset is summarised in Fig. 2b. Of the 46 patients where data is available, the most common manifestations were delay/impairments in: cognition (69.6%), speech (60.9%), motor (60.9%) and social (45.7%). In respect to neurological classification, speech delay was most common in early infantile (91.7%), whilst cognitive delay was most common in late infantile (78.9%) and adult (100%), with motor delay (33.3%) and cognitive delay (33.3%) predominant in juvenile onset.

Neuroimaging assessment data was available for 49 patients (Table 1). A normal MRI result was reported in 29 patients (59.2%). Abnormal MRI results were reported for 20 patients (40.8%), with 7 patients reporting 2 or more MRI findings. The most common abnormal findings were: cortical atrophy (N = 10), cerebellar atrophy (N = 9), and white matter changes (N = 3). CT scan results were available for 7 patients, where normal results were shown for 6 patients, and 1 patient shown to have an abnormal result with cortical atrophy.

Disease stage and progression

An assessment of disease severity was performed using a 6-domain disability scale (Pineda et al, 2010) to calculate the overall disability score according to the age-at-neurological-onset (Fig. 3). A total disability score was calculated for each patient by combining their ambulation, manipulation, speech, swallowing, eye movement, and seizure scores. Each subcategory was scored from normal to most severe based on the pre-defined validated disease progression domains.

Data on the age at diagnosis and age at death was available for 59 patients. Figure 4 provides an overview of patient data illustrating the recorded age at diagnosis, and the subsequent age at death, stratified according to the age of disease onset. In patients with the early infantile form (N = 15), the median ages at diagnosis and death were 0.5 years (0.1–1.8) and 5 years (0.8–7.0), respectively. In patients with the late infantile form (N = 13), the median ages at diagnosis and death were 4.3 years (2.9–4.0) and 9 years (4.0–16.0) respectively. In the juvenile onset group (N = 14), the median ages at diagnosis and death were 10 years (6.5–14.4) and 18 years (7.0–33.0) respectively. In patients with adult onset (N = 9), the median ages at diagnosis and death were 18.0 years (16.0–35.0) and 34.0 years (22.0–42.0) respectively. As anticipated, the age at diagnosis and death increased with increased age at neurological onset.

Treatment modalities

Data describing the symptomatic therapies used prior to or at enrolment was available for 85 patients. The mean total number of therapies used by each patient was 1.8. The most common symptomatic therapies used by patients were antiepileptics (32.9%), antidepressants (11.8%) and antacids (9.4%). The disease modifying therapy, Miglustat, was used by 62.4% of patients and the mean duration of use was 48.7 months. Diarrhoea was the most frequently reported adverse effect occurring in 56% of cases. Low platelet count was reported in 19% of cases and tremor was reported in 13% of cases.

Discussion

As NPC is a rare disease, patient population sizes are limited and tracking the natural history of the disease and enrolling patients for a clinical study is very challenging. The INPDR is a patient centric registry designed to: a) better understand the natural history of Niemann-Pick disease worldwide; b) provide an inventory of patients for recruitment to observational and interventional studies; c) establish genotype-phenotype correlations; d) provide support for education of health professionals and empowerment of patients. Data from 203 NPC patients from 6 countries were available for analysis, forming one of the largest cohorts of patients with NPC reported to date.

The p.I1061T variant was the most common variant in this population, with detection in 28.6% of patients. This aligns with previous research, where p.I1061T is most common in Western European decent populations (10) with varied frequency as reported in cohort studies from the United Kingdom (7), Spain (11), the Czech Republic (12), and Italy (13)

Disease classification based on the age of onset of the first neurological symptoms has been accepted as a guide to clinicians in providing day to day care, genetic counselling and estimate the trajectory of the disease course (10). The proportion of participants at each age category based on neurological onset was relatively consistent; 24.2% early infantile, 26.4% late infantile, 23.0% juvenile and 20.8% adult patients. These findings are in line with the previously reported observational studies (7, 9). The type and onset of visceral symptoms varied across the age groups with decreased occurrence with an increasing age. Neonatal jaundice and hepatomegaly were most prevalent in early infantile and late infantile patients. As has been reported in a prior NPC cohort study, splenomegaly is the most consistent observation across the age spectrum and was recorded in 80% of adult patients (6, 7, 9, 13).

Neurological signs such as ataxia, dysphagia, dysarthria and cognitive impairment were the most common, being reported in over two thirds of patients from all age categories. Similar to visceral manifestations, some of the neurological findings vary with age at disease onset. It is notable that the frequency of seizure and cataplexy is most common in infantile and juvenile onset and less so in adult. Developmental milestones delays were the most commonly reported neurological observation in early and late infantile forms. In contrast, psychiatric manifestations and hearing impairments are more common in adult onset. These observations are in agreement with previous observations (14).

Neuroimaging data gathered primarily from juvenile and adult individuals showed a variable pattern, with some being normal, while most patients imaging results demonstrate cortical and cerebellar atrophy as the most common changes. These changes have been reported to correlate with measures of ataxia and ocular-motor function (15).

Clinical assessment of disease burden and rate of progression in time or regression with disease modifying therapy is challenging when dealing with progressive diseases such as NPC. We used a modified 6-domain functional disability score (6) as calculated by combining ambulation, manipulation, speech, swallowing, eye movement and seizure scores. The composite disability scores were notably higher in patients with an early onset neurological signs, particularly in late infantile patients. This is consistent with the natural history of the disease, which has more severe presentation and rapid progression of the disease in patients whose neurological manifestations appear at a younger age (2). On the other hand, juvenile and adult-onset patients had fewer 'normal' individual disability scores for ambulation, manipulation and language domains. Eye movements and seizure seem to show the least variability indicating as less sensitive indicators to assess disease progression.

Mortality data was available for 59 patients and the duration of survival after disease onset varies with age spectrum of the disease. As expected, death on average resulted in less than one year of onset with the neonatal rapidly fatal forms. Interestingly, we observed a unique pattern with the other three age category of the disease as follow: early infantile, late infantile and juvenile form, where the mean rate of survival in years doubles for each category of NPC forms. In addition, similar longer survival trend was noted in adult forms. The lack of doubling effect in adult may well be due to long delayed diagnosis which in turn hampers the recognition and/or association of early subtle NPC related neuropsychiatric signs. The pattern of disease onset and survival observed in this study is largely in agreement with study from the French cohort (4). This observation can be used to council patients and families about the disease course and prognosis at the time of diagnosis.

Use of various therapeutic modalities was reported in this registry. The mean total number of therapies used by each patient was 1.84. The most common therapy was Miglustat, a potential disease modifying therapy specifically indicated for NPC, reported in 85 (62.4 %) patients, with a mean duration of just over 4 years. Other symptomatic therapies were antiepileptic (32.94%), antidepressants (11.76%) and antacids (9.41%). These levels of therapeutic intervention in NPC are in line with the current NPC international clinical management guidelines (16).

This study has some limitations: 1) Being an observational, non-interventional real-world study the dataset had some gaps in data points which may reflect variation in standard of care practice and needs of the patient. Therefore, some parameters were analysed with the denominator as "n" rather than 203 patients. 2) The data is a snapshot of the registry, with baseline data reported. Therefore longitudinal follow-up data should be considered to investigate the possible changes in disability score or neurological manifestations in line with existing and future disease modifying treatment. 3) Data reported is from 6 European countries, and may reflect the disease characteristics of patients from those

countries rather than being representative of patients globally. The capturing of clinical data from patients beyond these 6 countries may indicate differences to the findings of this analysis. The strength of our study lies on the use of the second largest number of NPC patients studied to date and its international scope. Above all, we have developed an exemplar patient led, independent international registry capable of delivering the unmet need of not only Niemann-Pick Disease but also serves as a model for other rare and neglected disorders.

In summary, the data of 203 NPC patient records captured via the INPDR highlights key patient and disease characteristics that can be tracked for future international studies. To our knowledge, this is the first patient led registry of such international reach. Long term longitudinal data utilising the INPDR on a larger international cohort is currently underway.

Methods

Study design and population

The International Niemann-Pick Disease Registry (INPDR) is a multi-centre, multi-national observational patient registry for the collection of Acid Sphingomyelinase Deficiency (ASMD) and NPC patient clinical data. The INPDR was launched in 2013 with the support of a European Commission grant and was developed through the involvement of expert clinicians, researchers and patient advocates from the global Niemann-Pick Disease community. The aim of the INPDR was the creation and maintenance of a web-based electronic data capture (EDC) platform to collect clinical data and patient reported data specific to Niemann-Pick Diseases (NPD). The EDC platform was developed by Sleek Ltd (Melbourne, Australia) and launched in 2014.

All patients with a confirmed diagnosis of NPD are eligible to be enrolled into the INPDR. Clinical data was captured using standard of care clinic visit information as source data, with assessments determined by the patient's clinician. Patients were recruited from six European countries, with research ethics committee approval obtained for all participating centres in line with applicable national and institutional research governance standards of the participating centres and the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines.

Data points and data collection

Data points were produced by a committee of expert clinicians, researchers and patient advocates and were adopted during a Scientific Advisory Committee meeting in 2013. The data points were grouped into the following data forms: patient demographics, biochemical and genetic testing, family history, clinical history, physical finding, treatment, disease severity scale, and additional investigations

All data was captured via the secure web-based INPDR EDC platform that allows clinicians and their authorised staff to enter clinical data of consented patients. The EDC platform IT infrastructure is currently maintained by OpenApp Ltd (Dublin, Ireland).

In line with the registry protocol, all collected data reflects the patient's standard of care practice as per the national clinical guidance. No assessments beyond standard of care were mandated by the protocol. Clinical data was entered by the centre's clinician or designated member of the clinician's staff. The baseline data was considered as data entered on or close to the informed consent date.

Statistical analysis

An extract of NPC baseline data from September 2014 to December 2019 was obtained from the EDC system. Data was extracted into a Microsoft Excel® file format (Microsoft Excel 2010, Microsoft Corporation). The descriptive data analysis was conducted using Microsoft Excel® to obtain the median and range of data points using the median formula (= MEDIAN(range)), the minimum value formula (= MIN(range), and maximum value formula (= MAX(range)). A CountIf formula (= COUNTIF(range, criteria)) was used to calculate the number of responses associated with a data point. For example, to count the number of 'Yes' responses to a data point, the formula = COUNTIF(range, "Yes") was used. Continuous variables are summarized using descriptive statistics including mean, standard deviation (SD), median, range and 95% confidence interval (CI) of the mean. Categorical variables are summarized using counts and percentages. All summary statistics and percentages were calculated relative to number of patients with available data. Denominators for analysis were the numbers of patients with the corresponding data available and hence different parameters may have different denominators.

Declarations

Ethics approval

This study was conducted in accordance with the Declaration of Helsinki and the International Conference for Harmonisation – Good Clinical Practice. This study was approved by the research ethics committees and institutional review boards of the participating centres.

Consent to participate

Written informed consent was obtained from study participants, parents or legal representatives.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

AD, BB, TH, SJ, PG and MTV has received travel grant from Actelion. MP has received travel grant from Actelion, Biomarin, Orpazyme, Esteve, Janssen and Chiesi. SB has received travel grant from Amicus Therapeutics and Sanofi Genzyme. Takeda has provided funding to TH, SJ, MTV, AD, BB and MP. Genzyme has provided funding to TH, YN, SJ, SS, JI, MH and MP. Orpazyme has provided funding to JI, AD and BB. Alexion has provided funding to MP. Vtesse has provided travel grants to MTV and MP. MP

has received funding from Agio, Amicus and Novartis. SJ has received funding from Biomarin, Ultragenyx, PTC and Orchard Therapeutics.

Funding

This publication arises from the project 'International Niemann-Pick Disease Registry' which has received funding from the European Union, in the framework of the Health Programme.

Authors' contributions

SCB and TG conceived the publication. All authors collected and analysed the data. SCB, VS, MTV and TG drafted the manuscript. All authors reviewed the draft and approved the final version. SCV, VS and TG are the guarantors of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis

Acknowledgements

This work was initiated by the International Niemann-Pick Disease Alliance (INPDA) and financially supported by the EU Directorate General for Health and Consumers via the Consumers, Health, Agriculture and Food Executive Agency (grant number 2012 120 NPDR). The authors would like to thank all INPDR partners and their institutions for their co-funding of the INPDR programme. The authors would also like to thank the Niemann-Pick Disease community for their participation and support for the INPDR.

Abbreviations

INPDR- International Niemann-Pick Disease Registry

NPC – Niemann-Pick Disease Type C

NPD – Niemann-Pick Disease

VSGP - Vertical Supranuclear Gaze Palsy

References

1. Hammond N, Munkacsi A, Sturley S. The complexity of a monogenic neurodegenerative disease: More than two decades of therapeutic driven research into Niemann-Pick type C disease. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*. 2019;1864(8):1109–1123.
2. Vanier M. Niemann-Pick disease type C. *Orphanet Journal of Rare Diseases*. 2010;5(1).
3. Lee S, Lee H, Kim S, Jeong Y, Jin H, Bae J, et al. Two Siblings with Adolescent/Adult Onset Niemann-Pick Disease Type C in Korea. *J Korean Med Sci*. 2016;31(7):1168.
4. Héron B, Valayannopoulos V, Baruteau J, Chabrol B, Ogier H, Latour P, et al. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. *Orphanet Journal of Rare*

- Diseases. 2012;7(1):36.
5. Iturriaga C, Pineda M, Fernández-Valero E, Vanier M, Coll M. Niemann–Pick C disease in Spain: Clinical spectrum and development of a disability scale. *J Neurol Sci.* 2006;249(1):1–6.
 6. Pineda M, Perez-Poyato M, O’Callaghan M, Vilaseca M, Pocovi M, Domingo R, et al. Clinical experience with miglustat therapy in pediatric patients with Niemann–Pick disease type C: A case series. *Mol Genet Metab.* 2010;99(4):358–66.
 7. Imrie J, Heptinstall L, Knight S, Strong K. Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database. *BMC Neurology.* 2015;15(1):257.
 8. Patterson M, Mengel E, Wijburg F, Muller A, Schwierin B, Drevon H, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. *Orphanet Journal of Rare Diseases.* 2013;8(1):12.
 9. Patterson M, Garver W, Giugliani R, Imrie J, Jahnova H, Meaney F, et al. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study. *J Inherit Metab Dis.* 2020;43(5):1060–9.
 10. Millat G, Marçais C, Rafi M, Yamamoto T, Morris J, Pentchev P, et al. Niemann-Pick C1 Disease: The I1061T Substitution Is a Frequent Mutant Allele in Patients of Western European Descent and Correlates with a Classic Juvenile Phenotype. *The American Journal of Human Genetics.* 1999;65(5):1321–9.
 11. Macías-Vidal J, Rodríguez-Pascau L, Sánchez-Ollé G, Lluch M, Vilageliu L, Grinberg D, et al. Molecular analysis of 30 Niemann-Pick type C patients from Spain. *Clin Genet.* 2010;80(1):39–49.
 12. Jahnova H, Dvorakova L, Vlaskova H, Hulkova H, Poupetova H, Hrebicek M, et al. Observational, retrospective study of a large cohort of patients with Niemann-Pick disease type C in the Czech Republic: a surprisingly stable diagnostic rate spanning almost 40 years. *Orphanet Journal of Rare Diseases.* 2014;9(1).
 13. Dardis A, Zampieri S, Gellera C, Carozzo R, Cattarossi S, Peruzzo P, et al. Molecular Genetics of Niemann–Pick Type C Disease in Italy: An Update on 105 Patients and Description of 18 NPC1 Novel Variants. *Journal of Clinical Medicine.* 2020;9(3):679.
 14. Wassif C, Cross J, Iben J, Sanchez-Pulido L, Cougnoux A, Platt F, et al. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. *Genet Sci.* 2015;18(1):41–8.
 15. Walterfang M, Patenaude B, Abel L, Klunemann H, Bowman E, Fahey M, et al. Subcortical Volumetric Reductions in Adult Niemann-Pick Disease Type C: A Cross-Sectional Study. *American Journal of Neuroradiology.* 2012;34(7):1334–40.
 16. Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Marfa M, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. *Orphanet Journal of Rare Diseases.* 2018;13(1).

Figures




Figure 1

A-C: Percentage of patients with (A) neonatal jaundice, (B) splenomegaly, and (C) hepatomegaly. N= total number of patients in category.





Figure 2

Neurological manifestations in relation to age at neurological onset (A). Developmental delay in relation to age of neurological onset (B). N= total number of patients in category.




Figure 3

A-F: Disability scale scores stratified by age at neurological onset. N= total number of patients in category.

Age at diagnosis and age at death




Figure 4

Age at diagnosis and death according to disease onset. Total number of patients = 59